DEMENT

CHICAGO, July 31 (Reuters) – Quest Diagnostics (DGX.N) on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer’s disease protein that can appear years before dementia symptoms arise. The $399 test, called AD-Detect, uses the same technology as a blood test the company began selling for use … Read more